Alnylam Pharmaceuticals (ALNY) focuses on treatments using ribonucleic acid interference and trades on Nasdaq with the ticker “ALNY.” The stock recently rebounded from a pullback at $442.51, and it expects to rise between $494.95 and $511.13. However, the company warns that chasing this rally could be risky, advising investors to wait for the next correction before buying.
According to Elliott Wave analysis, ALNY experienced a pullback to $31.38 in 2016, followed by a rise to $140 in 2025. Since then, the stock has continued to climb, hitting key marks but also facing corrections, especially after reaching $242.97. More growth is expected before the next anticipated correction.
Since April 2024, ALNY has achieved new highs, reaching $304.39 in mid-2025. Analysts suggest further movement during this phase, projecting a potential high of around $511.13, possibly extending to $570.76 before another correction. Despite this hopeful outlook, caution is urged regarding new immediate investments.
Legal and market disclaimers highlight the risks and uncertainties involved with this information. It is for informational purposes only and does not recommend any specific buy or sell actions. Given the risks in investing, individuals should conduct their own research before making decisions.
Alnylam Pharmaceuticals has continued to rally since the lows seen in April and July of 2025. The stock has now reached its target area between $494 and $511, making new long positions risky at this point. This surge appears to be the final phase of the current uptrend.
The strong rise during September and early October was mainly fueled by positive late-stage trial results for Zilebesiran, Alnylam’s hypertension drug. However, the Nasdaq Biotechnology Index (NBI) has weakened in the past month, dropping 4% since late September 2025. This slowing in the sector could impact even top performers like Alnylam.
For those trading derivatives, now might be the time to reduce long call positions and take profits. With the stock nearing its price targets, the danger of a sharp pullback is greater than the chance for immediate gains. Cautious investors might consider buying protective puts to shield their existing stocks from the expected downturn.
The main strategy for the coming weeks is to be patient and wait for the next correction. We will look for a dip that provides a better entry point for new bullish positions. This upcoming correction is a significant buying opportunity we are anticipating.
We saw a similar situation when the stock sharply pulled back in the first half of 2024, which led to the strong rally we’re seeing now. As long as any future correction stays above the July 2025 low of around $206, the overall upward trend remains intact. This level is the crucial support to watch.
here to set up a live account on VT Markets now
